Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.94 USD
Change Today -0.171 / -5.50%
Volume 54.0K
BTX On Other Exchanges
Symbol
Exchange
BTX is not on other exchanges.
As of 2:13 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

biotime inc (BTX) Key Developments

BioTime, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2015

BioTime, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $2,009,000, loss from operations of $13,496,000, loss before income tax benefit of $13,267,000, net loss attributable to company common shareholders of $9,743,000 or $0.12 per basic and diluted share compared to the total revenues of $1,107,000, loss from operations of $13,062,000, loss before income tax benefit of $12,907,000, net loss attributable to company common shareholders of $9,554,000 or $0.16 per basic and diluted share for the same quarter a year ago. For the six months period, the company reported total revenues of $3,268,000, loss from operations of $27,005,000, loss before income tax benefit of $27,049,000, net loss attributable to company common shareholders of $19,917,000 or $0.25 per basic and diluted share compared to the total revenues of $2,173,000, loss from operations of $24,183,000, loss before income tax benefit of $23,967,000, net loss attributable to company common shareholders of $17,643,000 or $0.29 per basic and diluted share for the same period a year ago.

BioTime, Inc., Annual General Meeting, Jul 10, 2015

BioTime, Inc., Annual General Meeting, Jul 10, 2015., at 10:30 US Eastern Standard Time. Location: 1221 Avenue of the Americas. Agenda: To elect ten directors to hold office until the next annual meeting of shareholders and until their respective successors are duly elected and qualified; to ratify the appointment of OUM & Co. LLP as the company's independent registered public accountants for the fiscal year ending December 31, 2015; to approve certain amendments to the BioTime Equity Incentive Plan; to hold an advisory vote on executive compensation; and to transact such other business as may properly come before the meeting or any adjournments of the meeting.

BioTime, Inc. and OncoCyte Corporation Announce Positive Interim Results from Lung Cancer Study

BioTime, Inc. and OncoCyte Corporation have announced positive interim clinical results demonstrating the high level of observed sensitivity and specificity in the assayed samples of a simple blood-based test designed for the early detection of lung cancer. The large, prospective clinical study was conducted by The Wistar Institute. The test was developed in the laboratory of Louise Showe, PhD, professor in the Molecular and Cellular Oncogenesis program of The Wistar Institute's NCI-designated cancer center. As part of the study, clinical investigators used a simple collection system that is approved by the FDA to prepare over 600 peripheral blood samples from patients determined to be at high risk for developing lung cancer based on age and smoking history. These patients were undergoing either low-dose computed tomography (CT) scanning for lung cancer or were recently diagnosed with lung cancer. Wistar scientists then assessed the expression of messenger RNA and micro RNA in the initial training set of 242 samples and developed a classifier of 145 markers (125 mRNAs plus 20 micro RNAs) that most accurately distinguished patients with malignant nodules from those with benign or no findings. The classifier was then assessed in an independent test set of 103 samples. Performance of the classifier was evaluated using several criteria, including Receiver Operating Characteristic (ROC) area under the curve (AUC) analysis, and yielded an AUC of 0.88 (sensitivity of 76% with a specificity of 88%) in the test set. Analysis of the full patient sample set is near completion. In October 2013, OncoCyte entered into a Sponsored Research Agreement with The Wistar Institute to identify, develop and test potential lung cancer biomarkers collaboratively with Dr. Showe's laboratory. OncoCyte has exercised options to obtain exclusive licenses to any inventions, discoveries or technology developed in the course of the collaborative research, including the technology presented and expects to negotiate definitive license agreements with Wistar.

BioTime, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 03:00 PM

BioTime, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 03:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Michael D. West, Chief Executive Officer, President and Director.

BioTime, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

BioTime, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total consolidated revenues of $1,264,454 against $1,066,635 million in the first quarter 2014. Net loss attributable to the company was $10,167,368 or $0.13 per basic and diluted share against $8,099,014 or $0.14 per basic and diluted share a year ago. Loss before income tax benefits was $13,766,937 against $11,077,057 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTX:US $2.94 USD -0.171

BTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Neuralstem Inc $1.52 USD 0.00
Ocata Therapeutics Inc $4.54 USD -0.31
Organovo Holdings Inc $2.53 USD -0.11
ReNeuron Group PLC 5.25 GBp 0.00
ReproCELL Inc ¥502.00 JPY -5.00
View Industry Companies
 

Industry Analysis

BTX

Industry Average

Valuation BTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 36.5x
Price/Book 17.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTIME INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.